《新股消息》和铂医药(02142.HK)公开超购逾77倍 一手中签率仅10%
和铂医药-B(02142.HK)公布招股结果,计划发行约1.38亿股当中10%为本地公开发售,公开发售录超购77.54倍,经重新分配後,公开发售股数增至40%。而国际发售初步可供认购的发售股份总数约8倍。
每股发售价定於12.38元,约中间价定价(招股价介乎每股11.7至12.92元),一手1,000股中签率为10%,抽20手才可稳夺一手。该股将於明日(10日)挂牌上市,由摩根士丹利、美国银行及中信证券担任联席保荐人。
是次招股将引入9个基石投资者,包括Black Rock Funds、HBM Health、高瓴资本、Hudson Bay Capital及Octagon Investments、安澜资本投资、3W、奥博资本与君联资本,已认购合共5,761.2万股发售股份,合共相当於紧随全球发售完成後公司已发行股本约7.5%。
公司预计,所得款项净额约为15.99亿元,约37%将用於研发核心产品HBM9161及HBM9036;约23%用於开发支柱资产HBM4003、注册备案及潜在商业化;约15%用於其他候选药物的研发;约12%用於和铂抗体平台产生的创新型分子发现及合作项目;约5%用以改进平台技术;余下约8%为一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.